<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Genetic alterations in malignant tissues are potential targets for gene-based <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> therapies </plain></SENT>
<SENT sid="1" pm="."><plain>Alternatively, aberrant expression of certain specific genes associated with <z:e sem="disease" ids="C1608408" disease_type="Neoplastic Process" abbrv="">malignant transformation</z:e> may be envisioned to enhance the expression of chemosensitizing drugs </plain></SENT>
<SENT sid="2" pm="."><plain>Epstein-Barr virus (EBV)-related B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> are fatal complications of immunosuppression due to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e>, organ transplantation or congenital immune abnormalities </plain></SENT>
<SENT sid="3" pm="."><plain>The malignant cells latently infected with EBV typically express the transcription factor EBNA2 as one of nine latent <z:mp ids='MP_0001799'>viral</z:mp> genes </plain></SENT>
<SENT sid="4" pm="."><plain>We tested whether an EBNA2-responsive EBV promoter may selectively target EBV-related <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells by virus-regulated expression of a <z:e sem="disease" ids="C0812393,C0038661" disease_type="Mental or Behavioral Dysfunction;Injury or Poisoning" abbrv="">suicide</z:e> gene </plain></SENT>
<SENT sid="5" pm="."><plain>Using the BamC promoter driving a <z:chebi fb="0" ids="24753">hygromycin</z:chebi>-<z:chebi fb="0" ids="17748">thymidine</z:chebi> kinase fusion gene or controls, we demonstrated that sensitivity to <z:chebi fb="0" ids="465284">ganciclovir</z:chebi> was selectively enhanced in cells expressing EBNA2 </plain></SENT>
<SENT sid="6" pm="."><plain>Further, there was complete macroscopic regression of established B-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> in mice with <z:hpo ids='HP_0004430'>severe combined immunodeficiency</z:hpo> disease (<z:mp ids='MP_0002536'>SCID</z:mp> mice) treated with a single course of <z:chebi fb="0" ids="465284">ganciclovir</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>These data provide in vitro and in vivo support for a model of exploiting the molecular basis of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> development to enhance the specificity of gene therapy </plain></SENT>
</text></document>